Try our beta test site
203 studies found for:    pci-32765
Show Display Options
Rank Status Study
1 Active, not recruiting Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL
Condition: Leukemia
Interventions: Other: Heavy Water (2H2O);   Drug: PCI-32765
2 Completed A Study to Assess the Effect of Rifampin on the Pharmacokinetics of PCI-32765 in Healthy Participants
Condition: Healthy Participants
Interventions: Drug: PCI-32765;   Drug: Rifampin
3 Active, not recruiting A Study to Evaluate the Bruton's Tyrosine Kinase (Btk) Inhibitor PCI-32765 in Patients With Recurrent Mature B-Cell Neoplasms
Condition: Recurrent Mature B-cell Neoplasms
Intervention: Drug: PCI-32765
4 Completed A Study to Evaluate the Pharmacokinetics of PCI-32765 in Participants With Varying Degrees of Hepatic Impairment
Condition: Hepatic Impairment
Intervention: Drug: PCI-32765
5 Completed A Study to Determine the Absorption, Metabolism, and Routes of Excretion of (14C) Radiolabeled Ibrutinib in Healthy Male Participants
Condition: Healthy Participants
Intervention: Drug: Ibrutinib
6 Completed A Study of PCI-32765 (Ibrutinib) in Patients With Refractory Follicular Lymphoma
Condition: Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
7 Completed
Has Results
Safety and Efficacy Study of a BTK Inhibitor in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma
Condition: Diffuse Large Cell B-lymphoma
Intervention: Drug: ibrutinib
8 Active, not recruiting Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
Condition: Waldenstrom's Macroglobulinemia
Intervention: Drug: PCI-32765
9 Completed A Study to Assess the Absolute Bioavailability of Oral PCI-32765 and the Effect of Grapefruit Juice on the Bioavailability of PCI-32765 in Healthy Participants
Condition: Healthy Volunteer
Interventions: Drug: PCI-32765 (Treatment A);   Drug: PCI-32765 (Treatment B);   Drug: PCI-32765 (Treatment C);   Drug: 13C6 PCI-32765 (reference)
10 Completed A Pharmacokinetic Study in Healthy Participants to Assess the Pharmacokinetics and Safety of a Supratherapeutic Dose of PCI-32765 (Ibrutinib) Capsule and Solution Formulations Administered With Food
Condition: Healthy Volunteer
Interventions: Drug: Treatment A: PCI-32765;   Drug: Treatment B: PCI-32765
11 Recruiting A Study of Different Doses of Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: Ibrutinib
12 Active, not recruiting Trial of PCI-32765 (BTK Inhibitor) in Combination With Carfilzomib in Relapse/Refractory Mantle Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Ibrutinib;   Drug: Carfilzomib;   Behavioral: Phone Calls
13 Completed Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Lymphoma, Mantle-cell
Intervention: Drug: Ibrutinib
14 Enrolling by invitation A Long-term Extension Study of PCI-32765 (Ibrutinib)
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Diffuse Large B-cell Lymphoma
Intervention: Drug: PCI-32765 (Ibrutinib)
15 Active, not recruiting PCI-32765 (Ibrutinib) in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-cell Prolymphocytic Leukemia
Conditions: Prolymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory/Relapsed Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Other: Correlative laboratory samples;   Other: quality of life assessment
16 Active, not recruiting An Open Label Treatment Use Protocol for Ibrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Condition: Relapsed or Refractory Mantle Cell Lymphoma
Intervention: Drug: Ibrutinib
17 Active, not recruiting
Has Results
A Multicenter Phase 2 Study of PCI-32765 (Ibrutinib) in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) With 17p Deletion
Conditions: Chronic Lymphocytic Leukemia With 17p Deletion;   Small Lymphocytic Lymphoma With 17p Deletion
Intervention: Drug: PCI-32765
18 Completed
Has Results
Safety of PCI-32765 in Chronic Lymphocytic Leukemia
Conditions: B-cell Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: PCI-32765
19 Completed
Has Results
Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Condition: Mantle Cell Lymphoma
Intervention: Drug: PCI-32765
20 Recruiting RICE-ibrutinib in Relapsed DLBCL
Conditions: Diffuse Large B Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Recurrent
Intervention: Drug: Ibrutinib-RICE

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.